Covid-19 costs Coloplast USD 33m in extended court cases
Medtech company Coloplast has set aside a further USD 33m to pay for compensation in the remaning cases over its vaginal mesh product in the US. The covid-19 crisis has delayed court cases and increased the cost of legal counsel, but the financial director expects this amount to be enough to but the cases behind them.
BY ULRICH QUISTGAARD, TRANSLATED BY CATHERINE BRETT
In Coloplast's Q2 financial report released on Thursday there was a special column for the expensive cloud that is still hanging over the medtech company in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Coloplast raises EBIT margin guidance
For subscribers
Coloplast CEO on buying spree: "Something has to happen"
For subscribers
